8-K: BrainStorm Cleared for NurOwn Phase 3b ALS Trial

BrainStorm Cell Therapeutics announced FDA clearance for its NurOwn Phase 3b ALS trial and reported second quarter 2025 financial results, including an increased net loss.

Summary

• BrainStorm Cell Therapeutics received FDA clearance to initiate its Phase 3b clinical trial (ENDURANCE) for NurOwn in Amyotrophic Lateral Sclerosis (ALS).
• The ENDURANCE trial is designed to enroll approximately 200 participants, featuring a 24-week randomized, double-blind, placebo-controlled phase, followed by a 24-week open-label extension.
• Successful completion of the double-blind portion of the study is expected to generate clinical data to support a new Biologics License Application (BLA) submission.
• New survival data from the NurOwn Expanded Access Program (EAP) showed 100% (10/10) of participants survived more than 5 years from ALS symptom onset, compared to published estimates of approximately 10%. The median survival observed was 6.8 years.
• The company signed a Letter of Intent (LOI) with Minaris Advanced Therapies, a CDMO, to manufacture NurOwn for the upcoming Phase 3b clinical trial.
• NurOwn pharmacogenomic data was selected as Breakthrough Science for presentation at the ISCT 2025 Annual Meeting in May 2025.
• Cash, cash equivalents, and restricted cash were approximately $1.03 million as of June 30, 2025.
• Research and development expenses, net, for Q2 2025 were $1.1 million, up from $0.9 million in Q2 2024.
• General and administrative expenses for Q2 2025 were approximately $1.4 million, down from $2.1 million in Q2 2024.
• Net loss for Q2 2025 was approximately $2.9 million, compared to a net loss of approximately $2.54 million for Q2 2024.
• Net loss per share for Q2 2025 was $0.34, compared to $0.60 for Q2 2024, influenced by an increased weighted average number of shares outstanding (8,620,400 in Q2 2025 vs 4,747,699 in Q2 2024).

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant clinical and regulatory progress (FDA clearance for Phase 3b, promising EAP survival data, manufacturing partnership). However, this is tempered by a worsening net loss and a very low cash balance, indicating substantial financial challenges and a high likelihood of future capital raises.

Positives

• FDA clearance to initiate the Phase 3b clinical trial for NurOwn, a significant regulatory milestone.
• Encouraging survival data from the NurOwn Expanded Access Program, showing 100% of participants survived over 5 years from symptom onset, significantly higher than published estimates.
• Establishment of a manufacturing partnership with Minaris Advanced Therapies, ensuring readiness for clinical drug supply for the Phase 3b trial.
• NurOwn data selected as 'Breakthrough Science' for presentation at a major scientific meeting (ISCT 2025), highlighting scientific recognition.
• Decrease in general and administrative expenses to $1.4 million in Q2 2025 from $2.1 million in Q2 2024.

Negatives

• Increased net loss for the quarter ended June 30, 2025, reaching approximately $2.9 million, compared to $2.54 million in the prior year period.
• Low cash, cash equivalents, and restricted cash balance of approximately $1.03 million as of June 30, 2025, indicating a limited financial runway.
• Research and development expenditures increased to $1.1 million in Q2 2025 from $0.9 million in Q2 2024, reflecting increased trial costs.

Risks

• Ability to raise additional capital to fund ongoing operations and clinical trials.
• Ability to continue as a going concern given the current financial position.
• Prospects for future regulatory approval of NurOwn, which is not guaranteed.
• Uncertainty regarding whether future interactions with the FDA will have productive outcomes.

Future Outlook

The company is focused on executing its clinical development plan for NurOwn, with the Phase 3b trial designed to generate confirmatory data to support a potential Biologics License Application (BLA) submission. Management remains confident that NurOwn has the potential to make a meaningful difference for patients if approved. The company also supports the FDA's consideration of a Citizen Petition, which may provide a fresh opportunity for an objective evaluation of the scientific evidence.

Management Comments

• "BrainStorm remains focused on executing our clinical development plan for NurOwn."
• "We reached an important milestone in Q2 with FDA clearance to initiate our Phase 3b trial, designed to generate confirmatory data to support a potential BLA submission."
• "We are also advancing key operational activities, including discussions with clinical sites as well as ongoing engagement with our selected CDMO partners to ensure readiness for clinical drug supply."
• "We are encouraged by the ongoing interest and support from clinicians and the ALS community, and we remain confident that, if approved, NurOwn has the potential to make a meaningful difference for patients and their families."
• "We support the FDA's consideration of the Citizen Petition, which may provide a fresh opportunity for an objective evaluation of the scientific evidence."
• "We continue to stand behind the integrity and rigor of our data and will continue to engage with clinicians and the ALS community."

Industry Context

This announcement positions BrainStorm Cell Therapeutics as a key player in the development of advanced cell therapies for neurodegenerative diseases, particularly ALS. The FDA clearance for a Phase 3b trial for NurOwn is a significant step in a field with high unmet medical needs, where new therapeutic options are eagerly awaited by patients and clinicians. The company's focus on autologous stem cell therapies and its engagement with the ALS community reflect broader trends in personalized medicine and patient advocacy within rare disease drug development.

Comparison to Industry Standards

• The survival data from the NurOwn Expanded Access Program (EAP) showed 100% of participants (10/10) survived more than 5 years from the onset of ALS symptoms, which is significantly higher than published estimates indicating that approximately 10% of individuals with ALS would survive beyond 5 years. This comparison highlights a potentially strong outcome for NurOwn relative to the natural progression of ALS.

Stakeholder Impact

• Shareholders: Potential for significant value creation if NurOwn successfully completes trials and gains approval, but also risk of dilution from future capital raises given the current low cash position.
• Patients and ALS Community: Positive news regarding the advancement of a potential new therapy for ALS, offering hope for improved outcomes.
• Employees: Continued employment and operational activities are dependent on successful clinical development and securing adequate funding.
• Suppliers/Partners (e.g., Minaris Advanced Therapies): Continued business and collaboration opportunities related to the manufacturing and development of NurOwn.

Next Steps

• Initiate the Phase 3b clinical trial (ENDURANCE) for NurOwn.
• Engage in ongoing discussions with clinical sites for the Phase 3b trial.
• Continue engagement with selected CDMO partners to ensure readiness for clinical drug supply.
• Generate confirmatory clinical data from the Phase 3b trial to support a new Biologics License Application (BLA) submission.
• Monitor and potentially engage with the FDA regarding the Citizen Petition for a new review of NurOwn data.

Key Dates

Recommendation

While the FDA clearance for the Phase 3b trial and the encouraging EAP survival data represent significant clinical milestones for NurOwn, providing a clear path towards potential BLA submission, the company's financial health presents considerable risk. The increased net loss and critically low cash balance of $1.03 million strongly indicate an imminent need for capital raises, which will likely lead to shareholder dilution. A seasoned investor would acknowledge the clinical upside but remain cautious due to the substantial funding challenges and the inherent risks associated with late-stage clinical development in biotechnology.

Keywords

NurOwn, ALS, neurodegenerative disease, stem cell therapy, Phase 3b trial, FDA clearance, clinical trial, biotechnology, BCLI, BrainStorm Cell Therapeutics, Orphan Drug, Minaris Advanced Therapies, Expanded Access Program